INEPT
发表于 2025-3-21 16:44:39
书目名称Immunosurveillance, Immunodeficiencies and Lymphoproliferations影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0462292<br><br> <br><br>书目名称Immunosurveillance, Immunodeficiencies and Lymphoproliferations影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0462292<br><br> <br><br>书目名称Immunosurveillance, Immunodeficiencies and Lymphoproliferations网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0462292<br><br> <br><br>书目名称Immunosurveillance, Immunodeficiencies and Lymphoproliferations网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0462292<br><br> <br><br>书目名称Immunosurveillance, Immunodeficiencies and Lymphoproliferations被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0462292<br><br> <br><br>书目名称Immunosurveillance, Immunodeficiencies and Lymphoproliferations被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0462292<br><br> <br><br>书目名称Immunosurveillance, Immunodeficiencies and Lymphoproliferations年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0462292<br><br> <br><br>书目名称Immunosurveillance, Immunodeficiencies and Lymphoproliferations年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0462292<br><br> <br><br>书目名称Immunosurveillance, Immunodeficiencies and Lymphoproliferations读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0462292<br><br> <br><br>书目名称Immunosurveillance, Immunodeficiencies and Lymphoproliferations读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0462292<br><br> <br><br>
Fibrin
发表于 2025-3-21 23:23:30
http://reply.papertrans.cn/47/4623/462292/462292_2.png
勋章
发表于 2025-3-22 01:53:30
http://reply.papertrans.cn/47/4623/462292/462292_3.png
Supplement
发表于 2025-3-22 06:08:27
http://reply.papertrans.cn/47/4623/462292/462292_4.png
condone
发表于 2025-3-22 12:13:22
http://reply.papertrans.cn/47/4623/462292/462292_5.png
Curmudgeon
发表于 2025-3-22 14:17:34
http://reply.papertrans.cn/47/4623/462292/462292_6.png
同来核对
发表于 2025-3-22 18:37:37
http://reply.papertrans.cn/47/4623/462292/462292_7.png
GLUE
发表于 2025-3-22 22:55:27
Low-Dose Chemotherapy for Children with Post-Transplant Lymphoproliferative Disease,h late-onset PTLD (>2 years from transplant) more likely to relapse. Of the seven patients with relapsed PTLD, four were salvaged with “conventional” non-Hodgkin’s lymphoma chemotherapy. The overall 1-year survival for patients treated with low-dose chemotherapy was 86%. The estimated 2-year surviva
阶层
发表于 2025-3-23 03:37:53
Engineered Antibody for Treating Lymphoma, known as FcR. (the Brambell receptor): it is this receptor, present on endothelial cells, which recycles the molecule intact if it happens to be endocytosed and thus prolongs its metabolic life. Replacement of the mouse Fcγ by human Fcγ is expected to have three beneficial effects: better recruitme
Medicaid
发表于 2025-3-23 08:18:34
http://reply.papertrans.cn/47/4623/462292/462292_10.png